The MIF Knockout AGS Polyclonal Cells constitute a genetically disrupted cell population generated by CRISPR/Cas9-mediated targeting of the MIF locus in the AGS human gastric adenocarcinoma cell line. This polyclonal knockout product comprises a heterogeneous pool of edited cells, each harboring CRISPR-induced loss-of-function mutations in the MIF gene, thereby eliminating functional macrophage migration inhibitory factor (MIF) protein expression. The resulting population serves as a robust loss-of-function model for interrogating MIF-dependent signaling networks without the constraints of single-cell clonal selection. The polyclonal nature ensures genetic diversity that reduces clonal bias while maintaining uniform ablation of MIF activity. These cells are provided as a ready-to-use research tool for in vitro studies requiring MIF pathway disruption.
The host AGS cell line is derived from a human gastric adenocarcinoma and represents a well-established epithelial model for gastric cancer research. These adherent cells retain key characteristics of gastric carcinoma, including altered growth signaling, invasive potential, and pro-inflammatory cytokine production. AGS cells widely express receptors such as CD74 and CD44, which are critical co-receptors for extracellular MIF, making this line particularly suitable for studying MIF-dependent autocrine and paracrine signaling loops. The epithelial origin and genetic background of AGS cells provide a physiologically relevant context for gastric tumor biology, enabling the investigation of MIF??s role in cell proliferation, survival, and inflammation within a gastric cancer microenvironment.
MIF is a pleiotropic cytokine with intracellular and extracellular functions, including tautomerase activity and glucocorticoid counter-regulation. Upon secretion, MIF binds to the CD74/CD44 receptor complex, triggering downstream activation of Src family kinases, ERK1/2, PI3K, and Akt signaling cascades, which converge on NF-??B transcriptional programs. This promotes expression of pro-inflammatory cytokines (TNF-??, IL-6, IL-8), cell cycle regulators (cyclin D1), and anti-apoptotic proteins (Bcl-2), while suppressing p53 activity through interaction with JAB1/CSN5 and thioredoxin. Upstream, MIF expression is induced by hypoxia, HIF-1??, LPS, TNF-??, and NF-??B, forming positive-feedback loops. In AGS cells, MIF knockout disrupts CD74/CD44-mediated signaling, thereby reducing ERK1/2 and Akt phosphorylation, NF-??B activation, and downstream target gene expression, while derepressing p53-mediated apoptosis.
In the context of gastric adenocarcinoma, MIF overexpression correlates with tumor aggression, metastasis, and poor prognosis. The AGS MIF knockout model thus permits dissection of MIF??s contribution to gastric cancer hallmarks, including sustained proliferation, evasion of apoptosis, and enhanced cell motility. Loss of MIF function attenuates MAPK and PI3K/Akt pathway activity, impairing anchorage-independent growth and invasive capacity. Furthermore, the relief of p53 inhibition sensitizes cells to apoptotic stimuli, highlighting the therapeutic potential of MIF inhibition in gastric cancer. This model also enables studies of glucocorticoid counter-regulation, as MIF normally opposes glucocorticoid-mediated immunosuppression, and its absence may restore steroid sensitivity in inflammatory contexts.
Researchers can employ the MIF Knockout AGS Polyclonal Cells in a range of advanced applications, including gastric cancer signal transduction studies, drug target validation, and cytokine network analysis. Representative assays include western blotting for phospho-ERK1/2 and Akt to assess pathway activity, qPCR for MIF target genes (IL-6, TNF-??) to quantify transcriptional responses, flow cytometry with Annexin V to measure apoptosis, and Transwell migration/invasion assays to evaluate metastatic behavior. Additional techniques such as ELISA for MIF secretion, colony formation assays, and NF-??B luciferase reporter assays are well-suited to characterize MIF-dependent phenotypes. These cells provide a versatile platform for examining tumor microenvironment interactions and testing novel therapeutic interventions targeting the MIF-CD74 axis. For customized applications or further technical details, please contact Ascent Research.
